Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer

Next Previous
Trial Profile

A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danvatirsen (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Gemcitabine; Paclitaxel
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 21 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 14 Mar 2024 Planned End Date changed from 31 Dec 2025 to 6 Jun 2024.
  • 02 Nov 2022 Planned End Date changed from 30 Dec 2022 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top